报告题目:生物产业概述及实践
主讲人:周鹏飞(武汉友芝友生物制药有限公司CEO)
时间:2019年9月20日,下午2:30
地点:东12楼F201
个人简介
![](/__local/9/E6/4B/3E9C557119AC35790B2F159199E_A170AAB1_A4FF.png)
周鹏飞博士,武汉友芝友生物制药有限公司CEO、华中科技大学同济药学院客座教授,加拿大麦克马斯特大学分子免疫学博士,斯坦福大学肿瘤中心博士后。拥有20年以上药物开发及团队管理经验。曾就职于先灵葆雅、 中美冠科生物、辉瑞-冠科亚洲肿瘤研究中心。目前周博士共发表学术论文40余篇, 授权专利40余项。获武汉东湖新技术开发区第四批“3551光谷人才计划”;“十二五”“十三五”国家重大新药创制专项支持” 等多项荣誉。
Dr. Zhou has over 20 years of experience in clinical oncology and therapeutic biologic R&D. Prior to co-founding YZY Biopharma, he was the executive director of Immunology, Crown Bioscience Inc., a leading CRO company dedicated to translational oncology. Dr. Zhou has extensive and in-depth experience in cancer biology and immunology. Dr. Zhou started his career as a surgeon in oncology and then postdoctoral scientist in immunology at Stanford University and Schering-Plough Biopharma (currently Merck Laboratories). Dr. Zhou obtained his PhD in molecular immunology from McMaster University, Canada, and BS degree in medicine and MS degree in surgery (pediatric oncology) from Tongji Medical University, Wuhan China. Dr. Zhou has published more than 40 papers in immunology and 40 patents in antibody engineering and circulating tumor cells.